Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma
| Image |  |
|---|---|
| Description | scientific article published on 28 September 2013 |
| Author/s |
author: Nicholas J. Vogelzang Cora Sternberg Günter Niegisch Tomasz M Beer Toni K Choueiri Ulka Vaishampayan Kenneth Boucher Jonathan E Rosenberg |
| Publication date | September 28, 2013 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |